|
Jonathan Anker, MD, third-year fellow in Hematology and Medical Oncology, received a Young Investigator Award from the Bladder Cancer Advocacy Network for his project "Characterizing and Modulating TREM1 on SPP1 Macrophages to Overcome Resistance to Immunotherapy in Urothelial Cancer.” The Young Investigator Award recognizes early-career researchers who conduct novel studies to enhance the well-being of bladder cancer patients.
| |
|
Angela Liu, MD, has joined the Mount Sinai faculty as Instructor of Medicine (Hematology and Medical Oncology). She will be conducting clinical research on the proteomics of sickle cell disease, funded by a T32 grant in Emergency Medicine, with Jeffrey Glassberg, MD, and Susanna Curtis, MD. Dr. Liu will see patients with general hematologic conditions at Mount Sinai-Union Square and patients with sickle cell disease at the Mount Sinai Center for Advanced Medicine.
Dr. Liu earned her MD from Case Western Reserve University School of Medicine. She completed residency in Internal Medicine at Johns Hopkins Medicine and fellowship in Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai, serving as Chief Fellow in her final year. Her active research projects include a study of anticoagulation strategies in patients with sickle cell disease and thrombosis.
| |
|
The Division of Hematology and Medical Oncology welcomed eight new fellows on July 1.
The fellows, along with their medical schools and Internal Medicine residencies, are:
| |
|
Fionnuala Crowley, MD
University College Cork School of Medicine
Mount Sinai Morningside/West
Irina Krybaeva, MD
Yale School of Medicine
The Mount Sinai Hospital
Ademola Ojo, MD
Obafemi Awolowo University College of Health Sciences
Howard University Hospital
Noah Osei, MD
University of Ghana Medical School
Harlem Hospital Center
| |  |
|
Michelle Rudshteyn, MD
Rutgers New Jersey Medical School
The Mount Sinai Hospital
Dahniel Sastow, MD
Icahn School of Medicine at Mount Sinai
The Mount Sinai Hospital
Manik Uppal, MD
Weill Cornell Medicine
NewYork-Presbyterian/Weill Cornell Medicine
Graham Wehmeyer, MD
Weill Cornell Medicine
NewYork-Presbyterian/Weill Cornell Medicine
| |
|
Richard Bakst, MD, is the Proton Therapy Co-Chair for a multi-site phase II trial that studies the effect of pembrolizumab alone compared to the usual approach adjuvant chemo-radiotherapy after surgery in treating patients with recurrent head and neck squamous cell carcinoma with high-risk features including extranodal extension or positive margins. The trial utilizes proton beam radiotherapy in the radiation arm to reduce the risks associated with re-irradiation of the head and neck. It is currently open at The Blavatnik Family Chelsea Medical Center, Mount Sinai-Union Square and The Mount Sinai Hospital, and at the New York Proton Center.
The ECOG-ACRIN Cancer Research Group designed the trial and is conducting it with funding from the National Cancer Institute through its National Clinical Trials Network.
NCT04671667
| |
|
Oliver Van Oekelen, MD, PhD; Samir Parekh, MBBS, and colleagues
Charting the course: Sequencing immunotherapy for multiple myeloma
American Society of Clinical Oncology Educational Book. 2024 June. PMID: 38875506
Novel immunotherapeutic strategies for multiple myeloma (MM)—such as chimeric receptor antigen (CAR) T-cell and bispecific antibody (bsAb) therapies—that aim to harness the immune system against MM cells exhibit efficacy in treating relapsed/refractory MM. This book chapter provides a summary of the recent clinical data on CAR T-cell and bsAB therapies, clinical challenges with the administration of bsAb, biological basis for resistance mechanisms, and optimal sequencing approaches following CART or bispecific failure to optimize outcomes.
| |
|
Steven Itzkowitz, MD, and colleagues
AGA Clinical Practice Update on management of inflammatory bowel disease in patients with malignancy: Commentary
Clinical Gastroenterology and Hepatology. 2024 May 14. PMID: 38752967
Patients with inflammatory bowel diseases (IBD) are at increased risk of cancer from long-standing intestinal inflammation and/or the use of immunosuppressive therapies. This clinical practice update from authors who are experts in the diagnosis and management of IBD discusses the risks of various malignancies in patients with IBD and the impact of available medical therapies on these risks, and provides recommendations for managing patients with IBD who develop a malignancy, or who have a history of cancer.
| |
|
Jerry Edward Chipuk, PhD, was an invited lecturer and session chair at the International Cell Death Society meeting in Ghent, Belgium, held in May. The title of his presentation was: “BAX-dependent mitochondrial outer membrane permeabilization: Exquisitely regulated to the point of death.”
| |
|
Sacha Gnjatic, PhD, will be on the faculty for Cancer Immunotherapy Winter School, to be held February 11-14 by the Society for Immunotherapy of Cancer. Dr Gnjatic will present on T-Cell Receptor Sequencing as a biomarker for cancer. Early registration deadline is January 6.
| |
|
Tisch Cancer Institute Community Outreach and Engagement Retreat
A workshop focused on collaboration between research programs and the community to reduce cancer burden and promote equity in cancer care
Monday, September 30, 11 am–2 pm
Registration
| |
Mobile Mammography Celebration | |
|
Do you have news for the next issue of TCI Connections?
Please send to Janet.Aronson@mountsinai.org.
Remember to share breaking news and high impact news that might be appropriate for media coverage with the Press Office. This may include pending FDA drug/device approvals, studies/trial results being published in high-impact journals, and patient stories. The more lead time you can give the Press Office, the better—ideally, four weeks or when a paper is accepted by the journal. Embargoes will always be honored and news will only be released with your approval. Email the Press Office at NewsMedia@mssm.edu
| | |
Ramon Parsons, MD, PhD, Director
Janet Aronson , Editor
| | | | |
